"Xanthine Oxidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria.
| Descriptor ID |
D014969
|
| MeSH Number(s) |
D08.811.682.047.928
|
| Concept/Terms |
Xanthine Oxidase- Xanthine Oxidase
- Oxidase, Xanthine
- Hypoxanthine Oxidase
- Oxidase, Hypoxanthine
- Purine-Xanthine Oxidase
- Oxidase, Purine-Xanthine
- Purine Xanthine Oxidase
- Hypoxanthine Dehydrogenase
- Dehydrogenase, Hypoxanthine
- Hypoxanthine-Xanthine Oxidase
- Hypoxanthine Xanthine Oxidase
- Oxidase, Hypoxanthine-Xanthine
|
Below are MeSH descriptors whose meaning is more general than "Xanthine Oxidase".
Below are MeSH descriptors whose meaning is more specific than "Xanthine Oxidase".
This graph shows the total number of publications written about "Xanthine Oxidase" by people in this website by year, and whether "Xanthine Oxidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xanthine Oxidase" by people in Profiles.
-
Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
-
Hare JM, Mangal B, Brown J, Fisher C, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008 Jun 17; 51(24):2301-9.
-
Freudenberger RS, Schwarz RP, Brown J, Moore A, Mann D, Givertz MM, Colucci WS, Hare JM. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure. Expert Opin Investig Drugs. 2004 Nov; 13(11):1509-16.
-
Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor JW, Jacobs ML, Wernovsky G, Mahle WT, Murphy JD, Nicolson SC, Steven JM, Spray TL. Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. Pediatrics. 2001 Jul; 108(1):61-70.
-
McGaurn SP, Davis LE, Krawczeniuk MM, Murphy JD, Jacobs ML, Norwood WI, Clancy RR. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome. Pediatrics. 1994 Dec; 94(6 Pt 1):820-3.
-
Di Giacomo C, Latteri F, Fichera C, Sorrenti V, Campisi A, Castorina C, Russo A, Pinturo R, Vanella A. Effect of acetyl-L-carnitine on lipid peroxidation and xanthine oxidase activity in rat skeletal muscle. Neurochem Res. 1993 Nov; 18(11):1157-62.
-
Vanella A, Sorrenti V, Castorina C, Campisi A, Di Giacomo C, Russo A, Perez-Polo JR. Lipid peroxidation in rat cerebral cortex during post-ischemic reperfusion: effect of exogenous antioxidants and Ca(++)-antagonist drugs. Int J Dev Neurosci. 1992; 10(1):75-80.
-
Spaeth G, Specian RD, Berg RD, Deitch EA. Splenectomy influences endotoxin-induced bacterial translocation. J Trauma. 1990 Oct; 30(10):1267-72.